Aspen Neuroscience, a San Diego, CA-based private biotechnology company developing autologous cell therapies including an iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), received $40M in Debt Financing.
Silicon Valley Bank provided the credit facility.
The company intends to use the funds to accelerate growth and expand operations.
Aspen Neuroscience is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs. The company combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments.
The company recently announced the achievement of key pre-clinical and corporate milestones, including raising $147.5m in Series B financing to support the planned studies of its lead product candidate for Parkinson’s Disease, ANPD001: a first-in-kind iPSC based autologous cell therapy. The company also recently announced the start of its trial ready patient screening cohort study for ANPD001.
FinSMEs
22/12/2022